Physician profile
Elbert R David
NPI 1861494924
$1,837.44
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,586 · 2020: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $319.97 | 2019-2020 | |
| Glaxosmithkline, LLC. | $266.65 | 2019-2020 | |
| Novo Nordisk INC | $248.93 | 2019-2020 | |
| Lilly USA, LLC | $160.85 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.17 | 2019 | |
| Janssen Pharmaceuticals, INC | $123.44 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $112.75 | 2019 | |
| Amarin Pharma, INC. | $66.15 | 2019-2020 | |
| Shire North American Group INC | $50.66 | 2019 | |
| Genentech USA, INC. | $44.00 | 2019 | |
| Abbvie INC. | $41.91 | 2019 | |
| Amneal Pharmaceuticals LLC | $33.23 | 2019 | |
| Antares Pharma, INC. | $32.55 | 2019-2020 | |
| Pfizer INC. | $32.10 | 2019 | |
| Arbor Pharmaceuticals, INC. | $29.68 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.78 | 2019-2020 | |
| Horizon Therapeutics Plc | $26.36 | 2019-2020 | |
| Ibsa Pharma INC. | $18.86 | 2019 | |
| Aytu Biopharma, INC. | $15.94 | 2019 | |
| Astellas Pharma US INC | $15.35 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.64 | 2020 | |
| Neos Therapeutics, LP | $12.60 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.87 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elbert David listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.